The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: 1) EDX Medical, Spire Healthcare Sign Diagnostic Testing Memorandum of ...

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

NEW YORK – Quanterix said Monday that its HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration from South Korea's Ministry of Food and Drug Safety (MFDS) through the firm's ...

The test uses machine learning to analyze biomarkers and clinical features to determine prostate cancer aggressiveness.

NEW YORK – HU Group Holdings subsidiary Fujirebio announced Monday that its subsidiary Fujirebio Diagnostics has acquired all shares of in vitro diagnostics and life science materials firm Plasma ...

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.

The ASM partnered with the US Centers for Disease Control and Prevention on the guidance published this month in Clinical Microbiology Reviews.

The Helsinki-based firm's test is used to automate breast cancer grading using AI-developed models, and it is integrated into the firm's breast cancer suite.

The company has reduced the turnaround time to a little over 48 hours for its pathogen-agnostic metagenomic next-generation sequencing test service for CNS infections ...

NEW YORK – The Association for Molecular Pathology on Tuesday published best practice recommendations for the design and validation of clinical tests for homologous recombination deficiency. The ...

The company hopes to complete proof of principle for a companion diagnostic to identify patients with PCa who are likely to need aggressive treatment.